📰 Alkermes News
Page 35 - Alkermes News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Alkermes. Real-time updates on events, politics, business and more.
May 29, 2023
DataBridge Market Research published latest research study on Self-injections market report examines market drivers, market restraints, challenges, opportunities and key developments in the Self-injections industry. An all-inclusive Self-injections market research report is formulated with the exact understanding of...
May 28, 2023
Colorado’s new Prescription Drug Affordability Board could cap what health plans and consumers pay for certain medications starting next year. The process New Colorado panel will determine which drug costs to cap but it will be a difficult decision
May 25, 2023
Catherine Reitzel's multiple sclerosis medication costs nearly $100,000 a year. Kris Garcia relies on a drug for a blood-clotting disorder that runs $10,000 for a three-day supply. And Mariana Marquez-Farmer would likely die within days without her monthly $300 vial of insulin.
May 25, 2023
Colorado’s new Prescription Drug Affordability Board could cap what health plans and consumers pay for certain medications starting next year. The process will pit patient groups against one another.
May 25, 2023
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) (the Company) today filed its definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) and...
May 25, 2023
Company Has Outperformed Peers and Relevant Indices Since Unveiling its December 2020 Value Enhancement Plan 70% of Board's Independent Directors Have Been Appointed Over the Last Four
May 25, 2023
With hundreds of expensive drugs to choose from, board members face tough decisions about who will get help now and who will have to wait.
May 25, 2023
Company Has Outperformed Peers and Relevant Indices Since Unveiling its December 2020 Value Enhancement Plan 70% of Boards Independent Directors Have Been Appointed Over the Last Four Years,... | June 11, 2023
May 23, 2023
Alkermes plc (NASDAQ:ALKS – Get Rating) has been given a consensus rating of “Buy” by the seven analysts that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers […]
May 22, 2023
StockNews.com initiated coverage on shares of Alkermes (NASDAQ:ALKS – Get Rating) in a report released on Thursday morning. The brokerage issued a strong-buy rating on the stock. Several other equities research analysts have also issued reports on the stock. Mizuho raised their target price on shares of Alkermes from $36.00 to $37.00 and gave the […]